C5
ENSG00000106804
Target class
Secreted protein
Chromosome
9
Approved drugs
6
Clinical candidates (approved and in development)
12
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- No
- Target name
- C5
- Gene name
- Complement C5
- Gene symbol
- C5
- Protein name
- Complement C5 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4) [Cleaved into: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5b (Complement C5 alpha' chain)]
- CPAMD4
- C5a
- C5b
- Gene biotype
- Protein coding
- Gene family
- Receptor ligands|C3 and PZP like, alpha-2-macroglobulin domain containing|Complement system activation components|Membrane Attack complex
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 51
- Highest tissue expression
- 121.08
- Tissue specificity (Gini)
- 0.554
- Tissue specificity (tau)
- 0.966
- KEGG gene identifiers
- hsa:727
- Protein interaction confidence
- 0.830077
- Protein interaction partners
- 39
- R-HSA-166665
- R-HSA-174577
- R-HSA-375276
- R-HSA-418594
- R-HSA-977606
- End position
- 121075195
- Start position
- 120932987
- Chromosome
- 9
- Strand
- Reverse
- Secreted .
- SUBCELLULAR LOCATION: [Complement C5b]: Secreted . Target cell membrane . Note=Secreted as soluble protein. Inserts into the cell membrane of target cells. .
- SUBCELLULAR LOCATION: [C5a anaphylatoxin]: Secreted .
- PubMed 106884
- PubMed 30552328
- PubMed 30643019
- PubMed 31061395
- PubMed 32569291
- PubMed 690134
- Tissue specificity (tau)
- 0.96584
- Expression inequality (Gini)
- 0.55435
Expression in transcripts per million
- Liver
- 121.08
- Nerve - Tibial
- 15.4
- Pancreas
- 8.39
- Artery - Coronary
- 8.34
- Artery - Tibial
- 7.71
Expression in transcripts per million
- Liver121.08
- Nerve - Tibial15.4
- Pancreas8.39
- Artery - Coronary8.34
- Artery - Tibial7.71
- Artery - Aorta7.47
- Cervix - Endocervix7.38
- Stomach7.06
- Cervix - Ectocervix7.03
- Uterus6.91
- Ovary6.89
- Fallopian Tube6.7
- Pituitary6.54
- Prostate6.41
- Lung6.27
- Esophagus - Gastroesophageal Junction5.37
- Colon - Sigmoid5.22
- Bladder4.97
- Esophagus - Muscularis4.76
- Adipose - Subcutaneous4.75
- Breast - Mammary Tissue4.69
- Cells - Cultured fibroblasts4.58
- Vagina4.4
- Adipose - Visceral (Omentum)4.01
- Skin - Not Sun Exposed (Suprapubic)3.88
And 29 more, listed on the interactive page.
- GO:0006935
- GO:0006954
- GO:0007166
- GO:0007186
- GO:0010575
- GO:0010760
- GO:0032722
- GO:0160257
- GO:0005576
- GO:0005579
- GO:0070062
- GO:0005102
- GO:0005515
- GO:0008009
Related records
Trials (238)
- A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
- A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
- A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
- A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
- A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
- A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)
- A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
- A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
- A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- A Study of a Single Dose of ALXN1210 in Healthy Participants
Drugs (13)
- Avacincaptad pegol sodium Complement C5 inhibitor
- Cemdisiran Complement C5 mRNA RNAi inhibitor
- Crovalimab Complement C5 inhibitor
- Eculizumab Complement C5 inhibitor
- Nomacopan Complement C5 inhibitor
- Olendalizumab Complement C5 inhibitor
- Pexelizumab Complement C5 inhibitor
- Pozelimab Complement C5 inhibitor
- Ravulizumab Complement C5 inhibitor
- Tesidolumab Complement C5 binding agent
- Vilobelimab Complement C5 inhibitor
- Zilucoplan Complement C5 inhibitor
- Zilucoplan sodium Complement C5 binding agent